Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IA-IB Open-label, Non-randomized, Neoadjuvant Treatment With Combination Pembrolizumab and Defactinib for Patients With Surgically Resectable Malignant Pleural Mesothelioma

NCT04201145 is registered in ClinicalTrials.gov with Raphael Bueno, MD as lead sponsor.

NCT NCT04201145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04201145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IA-IB Open-label, Non-randomized, Neoadjuvant Treatment With Combination Pembrolizumab and Defactinib for Patients With Surgically Resectable Malignant Pleural Mesothelioma
Lead sponsor
Raphael Bueno, MD
Phase
Phase 1
Overall status
Withdrawn
Start date
September 30, 2020
Completion date
December 31, 2022
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesothelioma